May 28, 2026
We are proud to showcase the depth and breadth of clinical oncology expertise and cancer research at UPMC Hillman Cancer Center presented at the ASCO 2026 Annual Meeting.
Explore our presentations, connect with our us, and discover how UPMC Hillman Cancer Center is shaping the future of oncology.
(All times in Central Time)
Saturday, May 30
Rapid Oral Presentations: Developmental Therapeutics-Immunotherapy
(Location E451)
8:00 - 8:06 AM
Udai Kammula, MD
Phase 2 trial of TIL therapy for metastatic uveal melanoma: Evaluation of T cell potency and an in situ precision biomarker.
8:12 - 8:18 AM
Vincent Edgar Reyes, MD
A radomized prospective trial evaluating duration of PD-1 and PD-L1 inhibitor therapy in advanced solid tumors.
8:30 - 8:36 AM
Matt Nguyen, MD
Clinical and translational study of p38 inhibitor pexmetinib plus nivolumab following anti–PD-1/L1 failure in advanced solid tumors.
Poster Session: 9:00 AM - 12:00 PM
(Location: Hall A)
Anushri Kulkarni, BS
Impact of neighborhood socioeconomic deprivation and diet quality on immune checkpoint blockade outcomes.
Poster Board: 269
Anwaar Saeed, MD
Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Poster Board: 175
Anwaar Saeed, MD
NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.
Poster Board: 445b
Sunday, May 31
9:24 - 9:36 AM
(Location: Arie Crown Theater)
Udai Kammula, MD
Oral Presentation - Developmental Therapeutics-Immunotherapy: Phase 2 basket trial of precision TIL therapy for immunotherapy-resistant advanced cancers.
Also 9:48- 10:00 AM Panel Question and Answer
Poster Session: 9:00 AM - 12:00 PM
(Location: Hall A)
John M. Kirkwood, MD
EA6232: A phase II double-blind trial of sulforaphane for therapeutic prevention of melanoma in patients with multiple atypical nevi and a prior history of melanoma.
Poster Board: 487b
Yana G. Najjar, MD
A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).
Poster Board: 480b
Micheal Bishara, DO
Prophylactic tocilizumab to mitigate cytokine release syndrome in patients receiving tarlatamab: A single‑center exploratory experience informed by bispecific antibody safety data.
Poster Board: 556
Monday, June 1, 2026
10:24 - 10:36 AM
(Location: S100bc)
Diwakar Davar, MD
Oral Presentation – Melanoma/Skin Cancers: Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
Poster Session: 1:30 - 4:30 PM
(Location: Hall A)
Priya Rastogi, MD
AI-driven risk stratification for distant recurrence in node-positive HR+/HER2− early breast cancer: Independent validation in the NSABP B-28 trial.
Poster Board: 43
Parham Habibzadeh, MD, MS
Elevated red blood cell distribution width-to-albumin ratio and incident cancer risk: A prospective cohort study.
Poster Board: 536
Tuesday, June 2, 2026
10:09 - 10:21 AM
(Location: S100bc)
Parham Habibzadeh, MD, MS
Oral Prevention – Risk Reduction, and Genetics: Beyond hematologic malignancies: Clonal hematopoiesis of indeterminate potential and the risk of solid tumors in the UK biobank.
